The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
Hao LiChao LiangDonglin KuangGuohao HuangMengfan ZhangPengfei ChenQingzhu ZhengWenze XuJianzhuang RenXinwei HanXuhua DuanPublished in: Cancer biology & therapy (2023)
DEB-TACE displays attenuated hepatic fibrosis progression and noninferior tolerance compared to cTACE in treating intermediate- or advanced-stage HCC patients.